Shukra Pharmaceuticals Ltd.
Snapshot View

100.00 +4.65 ▲4.9%

24 June 2022, 04:01:00 PM
Volume: 470

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.shukrapharmaceuticals.com
Market Cap 15.59 Cr.
Enterprise Value(EV) 18.95 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 4.80 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 20.75 Trailing Twelve Months Ending 2022-03
Industry PE 29.69 Trailing Twelve Months Ending 2022-03
Book Value / Share 104.43 Trailing Twelve Months Ending 2022-03
Price to Book Value 0.95 Calculated using Price: 99.55
Dividend Yield 0.50 Period Ending 2021-03
No. of Shares Subscribed 0.16 Cr. 1,565,675 Shares
FaceValue 10
Company Profile
The company is engaged in the business of manufacturing and trading of pharmaceuticals Products, laboratory testing.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.88%
1 Week
-3.71%
1 Month
+75.44%
3 Month
+58.60%
6 Month
+22.03%
1 Year
+72.12%
2 Year
+241.30%
5 Year
+91.02%
10 Year
+4594.84%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -562.23 -11.39 0.94 0.85 3.51 3.55 3.04 0.23 1.21
Return on Capital Employed (%) -26.76 -5.78 1.83 2.40 7.41 5.94 3.62 0.77 0.54
Return on Assets (%) -19.87 -4.80 0.72 0.67 2.78 2.44 1.76 0.11 0.55

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 0 14 14 14 15 15 15 15 16 16
Non Curr. Liab. 12 2 3 2 3 6 9 11 13 6
Curr. Liab. 2 2 1 1 2 3 4 7 6 12
Minority Int.
Equity & Liab. 14 18 18 17 19 24 28 34 35 35
Non Curr. Assets 10 11 11 11 12 16 17 19 20 19
Curr. Assets 3 7 7 6 7 8 11 14 15 16
Misc. Exp. not W/O
Total Assets 14 18 18 17 19 24 28 34 35 35

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 5 4 3 5 5 5 6 12 11 18
Other Income 0 0 1 0 0 0 0 0 0 3
Total Income 5 5 4 5 5 5 6 12 12 21
Total Expenditure -5 -5 -3 -4 -4 -4 -4 -10 -10 -18
PBIDT 1 0 1 1 2 2 2 2 2 3
Interest 0 0 0 0 0 0
Depreciation -1 -1 -1 0 0 -1 -1 -1 -1 -2
Taxation 0 0 0 -1 0 0 0 0 0
Exceptional Items -3 0 -1 0
PAT -3 -1 0 0 1 1 0 0 0 1
Adjusted EPS -3 -5 1 1 3 3 3 0 1 5

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -7 10 -3 -2 3 0 1 0 1 0
Cash Fr. Inv. 2 -11 2 1 0 -1 -5 -2 -3 -2
Cash Fr. Finan. 5 1 2 1 -1 3 2 2 2
Net Change 0 0 0 0 1 -1 0 0 0 0
Cash & Cash Eqvt 0 0 1 1 2 1 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 49.17 49.17 49.17 49.17 49.17 49.17 49.17 49.17 49.17
Public 50.83 50.83 50.83 50.83 50.83 50.83 50.83 50.83 50.83
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 10 Jun 2022
Clarification sought from Shukra Pharmaceuticals Ltd
The Exchange has sought clarification from Shukra Pharmaceuticals Ltd on June 9 2022 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.

The reply is awaited.
Sat, 28 May 2022
Board Meeting Outcome for Meeting Of Board Of Directors Held On 28.05.2022
1. Considered adopted and approved audited financial result for the quarter and year ended on 31st March 2022 along with the Auditors Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015.2. Appointment of CS Rupal Patel Practicing Company Secretary as Secretarial Auditor of the Company for the F.Y. 2021-22.3. Recommendation of final dividend of 5% (Rs. 0.50 per equity share of Rs. 10 each face value) for the Financial Year 2021-22 subject to the approval of shareholders in the ensuing Annual General Meeting.4. Reviewed business of the Company.
Sat, 28 May 2022
Financial Result For The Period Ended 31.03.2022
Considered adopted and approved audited financial result for the quarter and year ended on 31st March 2022 along with the Auditors Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015.

Technical Scans View Details

Fri, 24 Jun 2022
High Delivery Percentage High Delivery Percentage
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Entering 52 Week High Zone Close Entering 52 Week High Zone
High Increase 1 Month High Increase 1 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 197,729.19 824.10 -0.1%
Divi's Laboratories Ltd. 97,465.46 3,671.45 +0.1%
Cipla Ltd. 75,288.48 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. 71,702.79 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. 55,150.04 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. 48,693.19 2,877.70 +0.8%
Gland Pharma Ltd. 42,987.55 2,610.75 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 60.42 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 32.92 3,671.45 +0.1%
Cipla Ltd. Consolidated 2022-03 29.92 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.85 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 52.24 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 62.67 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2022-03 35.48 2,610.75 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 4.12 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8.31 3,671.45 +0.1%
Cipla Ltd. Consolidated 2022-03 3.61 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.73 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.78 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.18 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2022-03 6.01 2,610.75 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 0.10 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,610.75 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 14.13 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,610.75 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 14.13 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,610.75 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 19,159.59 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,610.75 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 824.10 -0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,671.45 +0.1%
Cipla Ltd. Consolidated 2021-03 2,401.30 933.05 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,308.00 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,835.60 -0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,877.70 +0.8%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,610.75 +0.1%

FAQ's On Shukra Pharmaceuticals Ltd.

Can I Buy Shukra Pharma Shares now?

What is the Share Price of Shukra Pharma?

What is the Relative Strength Index (RSI) Value of Shukra Pharma?

What is the Market Capital (MCAP) of Shukra Pharma?

What are the key metrics to analyse Shukra Pharma?

What is the Price Performance of Shukra Pharma?